You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Details for Patent: RE42461


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: RE42461
Title:Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
Abstract: Hydroxy-substituted azetidinone hypocholesterolemic agents of the formula ##STR00001## or a pharmaceutically acceptable salt thereof, wherein: Ar.sup.1 and Ar.sup.2 are aryl or R.sup.4-substituted aryl; Ar.sup.3 is aryl or R.sup.5-substituted aryl; X, Y and Z are --CH.sub.2--, --CH(lower alkyl)-- or --C(dilower alkyl)--; R and R.sup.2 are --OR.sup.6, --O(CO)R.sup.6, --O(CO)OR.sup.9 or --O(CO)NR.sup.6R.sup.7; R.sup.1 and R.sup.3 are H or lower alkyl; q is 0 or 1; r is 0 or 1; m, n and p are 0-4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1-6; and provided that when p is O and r is 1, the sum of m, q and n is 1-5; R.sup.4 is selected from lower alkyl, R.sub.5, --CF.sub.3, --CN, --NO.sub.2 and halogen R.sup.5 is selected from --OR.sup.6, --O(CO)R.sup.6, --O(CO)OR.sup.9, --O(CH.sub.2).sub.1-5OR.sup.6, --O(CO)NR.sup.6R.sup.7, --NR.sub.6R.sup.7, --NR.sup.6(CO)R.sup.7, --NR.sup.6(CO)OR.sup.9, --NR.sup.6(CO)NR.sup.7R.sup.8, --NR.sup.6SO.sub.2R.sup.9, --COOR.sup.6, --CONR.sup.6R.sup.7, --COR.sup.6, --SO.sub.2NR.sup.6R.sup.7, S(O).sub.0-2R.sup.9, --O(CH.sub.2).sub.1-10--COOR.sup.6, --O(CH.sub.2).sub.1-10CON.sup.6R.sup.7, --(lower alkylene)COOR.sup.6 and --CH.dbd.CH--COOR.sup.6; R.sup.6, R.sup.7 and R.sup.8 are H, lower alkyl or aryl-substituted Ic R.sup.9 is lower alkyl, aryl or aryl-substituted lower alkyl; are disclosed, as well as a method of lowering serum cholesterol by administering said compounds, alone or in combination with a cholesterol biosynthesis inhibitor, pharmaceutical compositions containing them; and a process for preparing them.
Inventor(s): Rosenblum; Stuart B. (West Orange, NJ), Dugar; Sundeep (San Jose, CA), Burnett; Duane A. (Bernardsville, NJ), Clader; John W. (Milton, VT), McKittrick; Brian A. (New Vernon, NJ)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:12/797,341
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent RE42461
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Drugs Protected by US Patent RE42461

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: RE42461

PCT Information
PCT FiledSeptember 14, 1994PCT Application Number:PCT/US94/10099
PCT Publication Date:March 30, 1995PCT Publication Number: WO95/08532

International Family Members for US Patent RE42461

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 0720599 ⤷  Sign Up 300132 Netherlands ⤷  Sign Up
European Patent Office 0720599 ⤷  Sign Up 0390018-0 Sweden ⤷  Sign Up
European Patent Office 0720599 ⤷  Sign Up 92545 Luxembourg ⤷  Sign Up
European Patent Office 0720599 ⤷  Sign Up SPC/GB03/023 United Kingdom ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.